CLINICAL TRIALS PROFILE FOR LAMIVUDINE; ZIDOVUDINE

All Clinical Trials for LAMIVUDINE; ZIDOVUDINE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00000831 ↗	Virologic Responses To New Nucleoside Regimens After Prolonged ZDV or ddI Monotherapy	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 2	1969-12-31	To elucidate the relationship between virologic risk factors and immunologic and clinical progression in patients receiving monotherapy in protocol ACTG 175, and to compare new treatment regimens with combinations of reverse transcriptase inhibitors in long-term recipients of monotherapy. Specifically, to determine, in patients who have been taking zidovudine (AZT) alone for a long time, whether it is beneficial to add lamivudine (3TC) to AZT or to switch to d4T alone, and also to determine, in patients who have been taking didanosine (ddI) alone for a long time, whether it is beneficial to add AZT or AZT/3TC to ddI. Characteristics of virus replication, pathogenicity, and resistance are thought to determine the durability of virologic and clinical response to nucleoside reverse transcriptase inhibitors. Previous results of ACTG 175 suggest that either a switch to ddI or addition of ddI in patients receiving AZT results in better clinical, virologic, and CD4 cell response compared to continuation of AZT alone.
NCT00000834 ↗	A Phase I Study of Methotrexate for HIV Infection	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 1	1969-12-31	To determine the safety and tolerance of methotrexate in HIV-infected patients. To determine the dose effective in modulating key markers of immune activation. To determine a dose suitable for Phase II or III evaluation in HIV-infected patients. In HIV infection, complete immunological clearance of the foreign antigen does not occur, resulting in chronic immune activation. Because chronic immune activation may contribute to disease progression in HIV infection, immunomodulators may have therapeutic value in early HIV disease prior to development of opportunistic infections. The clinical benefits of methotrexate appear to derive from an anti-inflammatory effect; thus, it may reduce the state of chronic immune activation.
NCT00000838 ↗	Antiviral Activity of and Resistance to Lamivudine in Combination With Zidovudine, Stavudine, or Didanosine	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 2	1969-12-31	To evaluate the efficacy, safety, and pharmacokinetics of lamivudine (3TC) combined with zidovudine (AZT), stavudine (d4T), or didanosine (ddI) in comparison with d4T or ddI monotherapy in HIV-infected patients with no prior nucleoside therapy. 3TC may be uniquely effective in combination with AZT due to the interaction of AZT and 3TC resistance mutations. One explanation is that the M184V mutation, which confers resistance to 3TC, suppresses AZT resistance. This benefit of 3TC may not extend to combination therapy with other nucleoside analogs.
NCT00000841 ↗	A Study of Indinavir Sulfate Plus Zidovudine (AZT) Plus Lamivudine in HIV-Infected Patients Who Have Taken AZT for Six or More Months	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 3	1969-12-31	To determine the clinical efficacy of indinavir sulfate or placebo in combination with zidovudine ( AZT ) and lamivudine ( 3TC ) in AIDS patients. Protease inhibitors such as indinavir sulfate may be effective in patients with advanced HIV disease who have received prior AZT therapy. Since studies suggest that triple drug therapy may have an advantage over both monotherapy and two drug therapy, the combination of indinavir sulfate with AZT and 3TC should be evaluated.
NCT00000861 ↗	The Addition of Indinavir to Anti-HIV Treatment in HIV-Infected Patients	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	N/A	1969-12-31	The purpose of this study is to evaluate the effect of immediate versus deferred indinavir (IDV) in addition to background therapy on disease progression or death in patients with CD4+ cell counts between 200 and 500 cells/mm3 and plasma HIV RNA levels >= 10,000 copies/ml. This study aims to examine two management strategies, immediate versus deferred IDV therapy, for their clinical effects in the context of background antiretroviral (AR) therapy, given according to current clinical practice. There is an urgent need to identify the optimal use of IDV in patient management, since clinical endpoint studies have not been completed in the United States. Since there is little information about the long term durability of clinical effects, and even less information about the timing of the initiation of protease inhibitor therapy, exploring the disease progression and survival impact of immediate versus delayed use of IDV will yield important information to guide clinical decision making for this group of patients.
NCT00000865 ↗	The Safety and Effects of 1592U89 Used Alone or in Combination With Other Anti-HIV Drugs in HIV-Infected Infants and Children	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 1	1969-12-31	To assess the steady state pharmacokinetic features, tolerance, and safety of orally administered 1592U89, given alone or in combination with other antiretroviral medications, in HIV infected infants and children. To establish doses of 1592U89 appropriate for future pediatric Phase II/III clinical trials. On the basis of the preclinical and clinical studies, 1592U89 appears to be a promising agent for treatment of HIV infection in children, either as an alternative to currently employed agents, or in combination therapy regimens. A liquid formulation of the drug is available; thus concurrent development of 1592U89 for children and adults is possible.

Clinical Trial Conditions for LAMIVUDINE; ZIDOVUDINE

Condition Name

Condition Name for LAMIVUDINE; ZIDOVUDINE
Intervention	Trials
HIV Infections	133
HIV	20
HIV Infection	10
Pregnancy	6

Condition MeSH

Condition MeSH for LAMIVUDINE; ZIDOVUDINE
Intervention	Trials
HIV Infections	152
Infections	34
Acquired Immunodeficiency Syndrome	33
Infection	28

Clinical Trial Locations for LAMIVUDINE; ZIDOVUDINE

Trials by Country

Trials by Country for LAMIVUDINE; ZIDOVUDINE
Location	Trials
Puerto Rico	41
Canada	40
Spain	34
South Africa	31
China	18

Trials by US State

Trials by US State for LAMIVUDINE; ZIDOVUDINE
Location	Trials
California	84
New York	68
Illinois	59
Florida	58
North Carolina	53

Clinical Trial Progress for LAMIVUDINE; ZIDOVUDINE

Clinical Trial Phase

Clinical Trial Phase for LAMIVUDINE; ZIDOVUDINE
Clinical Trial Phase	Trials
Phase 4	37
Phase 3	47
Phase 2/Phase 3	8

Clinical Trial Status

Clinical Trial Status for LAMIVUDINE; ZIDOVUDINE
Clinical Trial Phase	Trials
Completed	159
Unknown status	14
Terminated	7

Clinical Trial Sponsors for LAMIVUDINE; ZIDOVUDINE

Sponsor Name

Sponsor Name for LAMIVUDINE; ZIDOVUDINE
Sponsor	Trials
National Institute of Allergy and Infectious Diseases (NIAID)	69
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	21
Glaxo Wellcome	16

Sponsor Type

Sponsor Type for LAMIVUDINE; ZIDOVUDINE
Sponsor	Trials
Other	162
NIH	97
Industry	97

LAMIVUDINE + ZIDOVUDINE: Clinical Trials Update and Market Projection

Last updated: April 27, 2026

What is the current clinical-trial landscape for lamivudine + zidovudine?

Lamivudine and zidovudine are established antiretroviral agents used in HIV therapy. Public registries continue to show ongoing clinical activity driven by (1) refinement of treatment regimens, (2) safety and tolerability characterization across subpopulations, and (3) operational studies such as adherence, switching strategies, and regimen simplification. Trial activity is also shaped by global guidance and payer-driven switches among first-line and second-line regimens.

Practical interpretation for R&D and investment:

• The combination is not a “new molecular entity.” Trial programs tend to be incremental, often focusing on comparative effectiveness, safety signals, and regimen switching rather than first-in-class endpoints.
• Sponsor mix and trial endpoints typically track current-of-care standards (viral suppression, tolerability, resistance dynamics, and durability).

Which clinical-trial questions are still being tested?

Across ongoing and recently reported studies involving lamivudine and/or zidovudine in HIV treatment contexts, the recurring scientific questions include:

1. Durability of viral suppression on nucleos(t)ide backbones

   • How long patients maintain virologic control on lamivudine-based and zidovudine-based regimens when used in modern care pathways.

2. Resistance and treatment durability

   • Resistance emergence patterns when lamivudine is used despite the known resistance risk associated with M184V/I substitutions.
   • Clinical impact of zidovudine resistance and cross-resistance considerations.

3. Tolerability and toxicity management

   • Zidovudine-associated anemia and neutropenia monitoring and mitigation.
   • Lamivudine-associated adverse event profiling and tolerability in long-term use.

4. Operational and adherence strategies

   • Simplification and switching studies that aim to improve persistence and reduce regimen discontinuation.

5. Special populations

   • Studies that evaluate safety and efficacy in populations such as comorbidities, pediatric cohorts, or patients with prior antiretroviral exposure.

What does the market structure look like for lamivudine + zidovudine?

The market for lamivudine + zidovudine is dominated by:

• Generic supply (large manufacturers in multiple regions)
• Low to moderate pricing pressure driven by tendering, government procurement, and broad generic availability
• Formulation-driven competition (tablet strength, fixed-dose combinations where used, and distribution reliability)

Demand is anchored to:

• HIV treatment programs, especially in resource-constrained settings
• Guideline-based regimen composition in specific geographies and patient subsets
• Reimbursement and procurement cycles

Key market dynamic: Even where newer classes exist, lamivudine and zidovudine remain embedded in older and transitioning care pathways. The combination often persists in parts of the system where switching costs, supply continuity, or guideline heterogeneity matter.

Where does lamivudine + zidovudine still fit in 2026-era HIV care?

Despite the expansion of tenofovir-based backbones and integrase inhibitor options globally, lamivudine and zidovudine retain utility in defined contexts:

• Continuity of care for patients already stable on older nucleoside backbones
• Second-line or alternative backbone strategies in some programs where tenofovir access is constrained or where clinical decisions favor zidovudine-based regimens
• Tolerability-driven tailoring where zidovudine’s profile may be used with hematologic monitoring protocols
• Procurement inertia in high-volume procurement systems that use multi-year formularies

What is the competitive landscape?

Competition is shaped by:

• Generic entrants across major manufacturing hubs
• Tender-based pricing by volume and contract terms
• Local market authorization cycles and distributor networks
• Product form and logistics more than differentiation in pharmacology

Where “moat” exists for incumbents:

• Manufacturing scale and supply reliability
• Licensed brand reputation in specific national procurement programs
• Quality systems and regulatory track record

How should investors and R&D teams think about near-term growth?

Growth is constrained by the maturity of the molecule, but volume resilience can persist because HIV treatment demand is structural. Near-term performance hinges on:

• Whether programs keep zidovudine-containing regimens on formulary
• Switching pace from zidovudine to newer backbones
• Budget cycles and procurement preferences
• Patent and exclusivity status (generics generally dominate, so differentiation is limited)

Market projection: baseline, downside, and upside ranges

The lack of explicit, registries-confirmed trial and market revenue inputs in this response prevents building a fully quantified forecast tied to measured enrollment, geographies, and unit volumes. What can be stated with actionable precision is the projection logic that drives scenario outcomes for lamivudine + zidovudine:

Scenario drivers

• Formulary retention (zidovudine): the slower programs remove zidovudine-containing backbones, the longer demand persists.
• Switch adoption: faster uptake of tenofovir-based strategies reduces zidovudine demand.
• Supply and price elasticity: tender competition can stabilize volumes but compress revenue.
• Regional heterogeneity: policy and procurement differ by country income group, which sustains regional demand pockets.

Projection framework (directional)

• Base case: stable to modest decline in revenue, with stable-to-soft growth in units in markets where procurement inertia slows switching.
• Downside: accelerated guideline-driven removal of zidovudine plus strong generic price compression.
• Upside: longer formulary persistence for nucleoside backbones, coupled with stable procurement volumes and higher-than-expected tender pricing due to supply constraints.

Commercial implications: where diligence should be focused

For business professionals, the actionable diligence checklist for lamivudine + zidovudine focuses on procurement and switching:

1. National and regional formulary status

   • Track which countries still list zidovudine-containing backbones in current guidelines and preferred regimens.

2. Tender pricing and award cadence

   • Measure price per unit by contract cycle and supplier substitution rates.

3. Switching programs and clinical guidance updates

   • Quantify switching triggers (toxicity, resistance patterns, or procurement-driven backbone changes).

4. Manufacturing capacity and quality inspections

   • Ensure continuity because supply disruptions can shift demand temporarily but harm share when recoveries occur late.

5. Resistance and regimen durability evidence

   • Use emerging clinical evidence to support patient management protocols that preserve adherence and reduce discontinuation.

Key Takeaways

• The clinical-trial signal for lamivudine + zidovudine is incremental: studies focus on durability, safety, switching, and operational performance rather than novel mechanism discovery.
• The market is generic-dominated, with competition driven by tender pricing, supply reliability, and formulary retention.
• Near-term revenue growth is limited; unit demand can remain resilient where zidovudine-containing regimens persist, but switching acceleration and price compression remain the primary risks.
• Investment and R&D priorities should concentrate on procurement visibility, formulary duration for zidovudine backbones, and evidence that supports tolerability-managed long-term use.

FAQs

1) Is lamivudine + zidovudine still used in modern HIV regimens?

Yes, it is still used in defined clinical pathways and procurement systems, particularly where zidovudine-containing backbone regimens remain in formulary or where switching is delayed.

2) What is the main clinical risk associated with lamivudine-based use?

The main concern is treatment-emergent resistance patterns, especially substitutions linked to lamivudine resistance, which can affect regimen durability.

3) What is the most operationally relevant toxicity concern with zidovudine?

Hematologic toxicity, particularly anemia and neutropenia, which requires monitoring protocols in routine care.

4) Why does market growth appear constrained for this combination?

High generic penetration and mature clinical use reduce pricing power, and regimen switching toward newer backbones compresses revenue growth.

5) What would most change market direction over the next few years?

Speed of formulary switching away from zidovudine backbones in major procurement regions and the resulting tender dynamics that determine unit volumes and pricing.

References

[1] U.S. Food and Drug Administration. Drug Development & Drug Interactions databases. https://www.fda.gov/drugs (accessed 2026-04-28).